JCO oncology practice
Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration.
Pasquale F Innominato, Thierry Landré, Abdoulaye Karaboué, Boris Duchemann, Zachary S Buchwald, Yongchang C Zhang, Dawn Griffiths, Christos Chouaïd, Francis A Lévi
Published: 202510.1200/OP-25-00661
Abstract
Immune checkpoint inhibitors (ICI) are a core mainstay of cancer care. In routine practice, the Time of Day of Administration (ToDA) of ICIs invariably is not stipulated in the clinical notes. Thus, treatment timing of administration is mainly dictat…
Preview only. Read the full abstract at the source